SAFETY DATA SHEET



1. Identification

Product identifier Temaril-P® Tablets

Other means of identification

Synonyms VANECTYL P * VANECTYL * TEMARIL * Trimeprazine tartrate and prednisolone

tablets

Recommended use Veterinary product used as anti-itch treatment (antipruritus), antitussive, anti-inflammatory

Recommended restrictions Not for human use

Manufacturer/Importer/Supplier/Distributor information

Company Name (US) Zoetis Inc.

10 Sylvan Way

Parsippany, New Jersey 07054 (USA)

Rocky Mountain Poison

and Drug Center

1-866-531-8896

Product Support/Technical

Services

1-800-366-5288

Emergency telephone

numbers

CHEMTREC (24 hours): 1-800-424-9300

International CHEMTREC (24 hours): +1-703-527-3887

Company Name (EU) Zoetis Belgium S.A.

Mercuriusstraat 20 1930 Zaventem

Belgium

Emergency telephone

number

International CHEMTREC (24 hours): +1-703-527-3887

Contact E-Mail VMIPSrecords@zoetis.com

2. Hazard(s) identification

Physical hazards Not classified.

Health hazards Sensitization, respiratory Category 1

Reproductive toxicity (the unborn child)

Category 1B

Specific target organ toxicity, single exposure

Category 1 (heart)

Specific target organ toxicity, repeated Category 1 (nervous system)

exposure

Environmental hazards Not classified.

OSHA defined hazards Not classified.

Label elements



Signal word Danger

Hazard statement May cause allergy or asthma symptoms or breathing difficulties if inhaled. May damage the

unborn child. Causes damage to organs (heart). Causes damage to organs (nervous system)

through prolonged or repeated exposure.

Precautionary statement

Prevention Obtain special instructions before use. Do not handle until all safety precautions have been read

and understood. Do not breathe dust/fume/gas/mist/vapors/spray. Wash thoroughly after handling. Do not eat, drink or smoke when using this product. Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory

protection.

Material name: Temaril-P® Tablets

SDS US

159 Version #: 03 Revision date: 05-04-2017 Issue date: 09-04-2013

If exposed or concerned: Get medical advice/attention. If inhaled: If breathing is difficult, remove Response

person to fresh air and keep comfortable for breathing. If experiencing respiratory symptoms: Call

a poison center/doctor.

Store locked up. Storage

Disposal Dispose of contents/container in accordance with local/regional/national/international regulations.

Hazard(s) not otherwise classified (HNOC)

None known.

Supplemental information Individuals sensitive to this material or other materials in its chemical class may develop allergic

reactions.

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Acacia		9000-01-5	<5
Cellulose		9004-34-6	<5
Magnesium stearate		557-04-0	<1
Calcium sulfate		7778-18-9	
Corn Starch		9005-25-8	
Prednisolone (Anhydrous)		50-24-8	2 mg
Trimeprazine Tartrate		4330-99-8	5 mg

Composition comments

In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

4. First-aid measures

Move to fresh air. If experiencing respiratory symptoms: Call a POISON CENTER or Inhalation

doctor/physician. If breathing is difficult, trained personnel should give oxygen.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists. Wash

contaminated clothing before reuse.

Immediately flush with plenty of water for at least 15 minutes. If easy to do, remove contact lenses. Eye contact

Continue rinsing. Get medical attention if irritation develops and persists.

Ingestion Rinse mouth. Get medical advice/attention if you feel unwell. Get medical attention if symptoms

occur. If ingestion of a large amount does occur, call a poison control center immediately. Do not induce vomiting without advice from poison control center. Never give anything by mouth to a

victim who is unconscious or is having convulsions.

Most important

symptoms/effects, acute and

delayed

Fatigue. Dizziness. Narcosis. Behavioral changes. Decrease in motor functions. Difficulty in breathing. May cause decreases in blood pressure and other cardiac effects. Prolonged exposure may cause chronic effects. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual irregularities, facial hair growth, and mental changes. Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia, confusion, tremors, headache, and gastrointestinal disturbances.

Indication of immediate medical attention and special treatment needed

General information

Provide general supportive measures and treat symptomatically. Keep victim under observation. Symptoms may be delayed. Monitor respiratory, cardiac and central nervous system. Clinical use has resulted in changes in electrolytes and/or blood chemistry changes.

For personal protection, see section 8 of the SDS. IF exposed or concerned: Get medical advice/attention. Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves. Show this safety data sheet to the doctor in attendance.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

Water fog. Foam. Dry chemical powder. Carbon dioxide (CO2). Do not use water jet as an extinguisher, as this will spread the fire.

Specific hazards arising from the chemical

Special protective equipment

During fire, gases hazardous to health may be formed.

and precautions for firefighters Fire fighting Use water spray to cool unopened containers.

equipment/instructions Specific methods

Use standard firefighting procedures and consider the hazards of other involved materials.

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Accidental release measures

Personal precautions, protective equipment and emergency procedures Keep unnecessary personnel away. Ensure adequate ventilation. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Avoid the generation of dusts during clean-up. Avoid inhalation of dust. Avoid contact with eyes, skin, and clothing. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8 of the SDS.

Methods and materials for containment and cleaning up

Ensure adequate ventilation. Remove sources of ignition. Wear appropriate protective equipment and clothing during clean-up.

Large Spills: Stop the flow of material, if this is without risk. Absorb in vermiculite, dry sand or earth and place into containers. Following product recovery, flush area with water.

Small Spills: Wipe up with absorbent material (e.g. cloth, fleece). Clean surface thoroughly to remove residual contamination.

Never return spills to original containers for re-use. For waste disposal, see section 13 of the SDS. Avoid discharge into drains, water courses or onto the ground.

Environmental precautions

7. Handling and storage

Precautions for safe handling

Use this product with adequate ventilation. Avoid contact with eyes, skin, and clothing. If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with eyes. Avoid prolonged exposure. Minimize dust generation and accumulation. When using, do not eat, drink or smoke. Wash thoroughly after handling. Wear appropriate personal protective equipment. Avoid release to the environment.

Conditions for safe storage, including any incompatibilities

Store locked up. Keep tightly closed in a dry, cool and well-ventilated place. @ 15 - 25°C (59 - 77°F). Keep away from heat and sources of ignition. Store away from incompatible materials (see Section 10 of the SDS). Keep out of the reach of children.

8. Exposure controls/personal protection

Occupational exposure limits

The following constituents are the only constituents of the product which have a PEL, TLV or other recommended exposure limit. At this time, the other constituents have no known exposure limits.

Zoetis			
Components	Туре	Value	
Prednisolone (Anhydrous) (CAS 50-24-8)	TWA	5 μg/m³	
US. OSHA Table Z-1 Limits for Air	Contaminants (29 CFR 1910.1	1000)	
Components	Туре	Value	Form
Calcium sulfate (CAS 7778-18-9)	PEL	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
Cellulose (CAS 9004-34-6)	PEL	5 mg/m3	Respirable fraction.
		15 mg/m3	Total dust.
Corn Starch (CAS 9005-25-8)	PEL	5 mg/m3	Respirable fraction.
,		15 mg/m3	Total dust.
US. ACGIH Threshold Limit Value	s		
Components	Туре	Value	Form
Calcium sulfate (CAS 7778-18-9)	TWA	10 mg/m3	Inhalable fraction.
Cellulose (CAS 9004-34-6)	TWA	10 mg/m3	
Corn Starch (CAS 9005-25-8)	TWA	10 mg/m3	
Magnesium stearate (CAS 557-04-0)	TWA	10 mg/m3	
US. NIOSH: Pocket Guide to Chen	nical Hazards		
Components	Туре	Value	Form
Calcium sulfate (CAS 7778-18-9)	TWA	5 mg/m3	Respirable.

Material name: Temaril-P® Tablets

Components	Туре	Value	Form
		10 mg/m3	Total
Cellulose (CAS 9004-34-6)	TWA	5 mg/m3	Respirable.
		10 mg/m3	Total
Corn Starch (CAS 9005-25-8)	TWA	5 mg/m3	Respirable.
,		10 mg/m3	Total

Biological limit values No biological exposure limits noted for the ingredient(s).

OEL Additional Information: Skin (May be absorbed through the skin and cause systemic effects.) **Exposure guidelines** Trimeprazine tartrate: Zoetis OEB 3 (control exposure to the range of 10ug/m3 to < 100ug/m3) Control banding approach

Appropriate engineering controls

Ensure adequate ventilation, especially in confined areas. Keep air contamination levels below the

exposure limits or within the OEB range listed above in this section.

Individual protection measures, such as personal protective equipment

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection Impervious gloves. Wear impervious, disposable gloves as minimum protection (double

recommended).

Other Wear suitable protective clothing. Impervious protective clothing is recommended if skin contact

with drug product is possible and for bulk processing operations.

In case of insufficient ventilation, wear suitable respiratory equipment. Respirator must be worn if Respiratory protection

exposed to dust. If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL. If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the

OEB range.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

General hygiene considerations

Observe any medical surveillance requirements. Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

9. Physical and chemical properties

Tablet. **Appearance** Solid. Physical state Solid. **Form**

Not available. Color Not available. Odor **Odor threshold** Not available. Not available. Hq Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Flash point Not available. Not available. **Evaporation rate** Flammability (solid, gas) Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

Flammability limit - upper

(%)

Not available.

Explosive limit - lower (%) Not available. Explosive limit - upper (%) Not available.

Not available. Vapor pressure Not available. Vapor density

Material name: Temaril-P® Tablets

Not available. Relative density

Solubility(ies)

Solubility (water) Not available. Not available. **Partition coefficient** (n-octanol/water)

Not available. **Auto-ignition temperature** Not available. **Decomposition temperature** Not available. **Viscosity**

Other information

Not explosive. **Explosive properties** Not oxidizing. Oxidizing properties

10. Stability and reactivity

Reactivity The product is stable and non-reactive under normal conditions of use, storage and transport.

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials. Avoid heat, sparks, open flames and other ignition sources.

Aluminum. Phosphorus. Strong oxidizing agents. Incompatible materials

Hazardous decomposition

products

Irritating and/or toxic fumes and gases may be emitted upon the product's decomposition.

11. Toxicological information

Information on likely routes of exposure

May cause allergy or asthma symptoms or breathing difficulties if inhaled. Prolonged inhalation Inhalation

may be harmful.

Skin contact Prolonged skin contact may cause temporary irritation. May be absorbed through the skin and

cause systemic effects.

Direct contact with eyes may cause temporary irritation. Eye contact

Species: Rabbit Acacia

Severity: Severe

Ingestion may result in mild gastrointestinal irritation with nausea, vomiting, or diarrhea. However, Ingestion

ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to the physical, chemical and toxicological characteristics Fatigue. Dizziness. Narcosis. Behavioral changes. Decrease in motor functions. Difficulty in breathing. May cause decreases in blood pressure and other cardiac effects. Prolonged exposure may cause chronic effects. Drugs of this class may cause Cushing's syndrome, manifested by moon face, obesity, headache, acne, thirst, increased urination, impotence, menstrual

irregularities, facial hair growth, and mental changes. Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia, confusion, tremors, headache, and

gastrointestinal disturbances.

Information on toxicological effects

Acute toxicity Expected to be a low hazard for usual industrial or commercial handling by trained personnel.

Product Species Test Results

Temaril-P® Tablets

Acute Oral

ATE

5000 mg/kg

Components **Species Test Results**

Cellulose (CAS 9004-34-6)

Acute

Dermal

LD50 Rabbit > 2000 mg/kg

Inhalation

LC50 Rat > 5.05 mg/l/4h

Material name: Temaril-P® Tablets 159 Version #: 03 Revision date: 05-04-2017 Issue date: 09-04-2013

Components **Species Test Results** Oral LD50 Rat > 5000 mg/kg Magnesium stearate (CAS 557-04-0) Acute Inhalation LC50 Rat > 2000 mg/m3 Oral LD50 Rat > 2000 mg/kg Prednisolone (Anhydrous) (CAS 50-24-8) **Acute** Intraperitoneal LD50 Mouse 65 mg/kg Oral LD50 Mouse 1680 mg/kg Chronic Oral LOAEL Guinea Pig 1 mg/kg/day, 24 weeks (Target organs: Bone, Blood) **Subacute** Oral LOAEL Dog 2.5 mg/kg/day, 6 weeks (Target organs: Adrenal gland, Liver) Rat 10.1 mg/kg, 4 days (Target organs: None identified)

Trimeprazine Tartrate (CAS 4330-99-8)

Acute

Intravenous

LD50 Rat 35 mg/kg

Oral

LD50 Mouse 300 mg/kg Rat 210 mg/kg

Skin corrosion/irritation Serious eye damage/eye irritation

Prolonged skin contact may cause temporary irritation. Direct contact with eyes may cause temporary irritation.

Eye Contact

Acacia

Species: Rabbit Severity: Severe

Respiratory or skin sensitization

Respiratory sensitization May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Skin sensitization This product is not expected to cause skin sensitization.

Germ cell mutagenicity No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Mutagenicity

Prednisolone (Anhydrous) Cytogenetics

Result: Negative

Species: Human Lymphocytes

In Vivo Mammalian Cell Mutagenicity

Result: Negative

Species: Mouse Lymphoma

Material name: Temaril-P® Tablets SDS US 6/9 Mutagenicity

Prednisolone (Anhydrous) Sister Chromatid Exchange

Result: Negative

Species: Human Lymphocytes

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA.

IARC Monographs. Overall Evaluation of Carcinogenicity

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated.

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Reproductive toxicity May damage the unborn child.

Developmental effects

Prednisolone (Anhydrous) 0.5 mg/day Embryo / Fetal Development, Teratogenic

Result: LOEL Species: Mouse

Organ: No route specified

2.5 mg/kg Embryo / Fetal Development, Teratogenic

Result: LOEL Species: Rat

Organ: Subcutaneous

Reproductivity

Prednisolone (Anhydrous) 250 - 600 mg/kg/day Reproductive & Fertility, Teratogenic

Result: LOAEL Species: Rat Organ: Oral

Specific target organ toxicity -

single exposure

Causes damage to organs (heart).

Specific target organ toxicity -

repeated exposure

Causes damage to organs (nervous system) through prolonged or repeated exposure.

Aspiration hazard Not an aspiration hazard.

Chronic effects Prolonged exposure may cause chronic effects.

12. Ecological information

Ecotoxicity The product is not classified as environmentally hazardous. However, this does not exclude the

possibility that large or frequent spills can have a harmful or damaging effect on the environment.

Avoid release to the environment.

Components Species Test Results

Calcium sulfate (CAS 7778-18-9)

Aquatic

Fish LC50 Fathead minnow (Pimephales promelas) > 1970 mg/l, 96 hours

Persistence and degradability No data is available on the degradability of this product.

Bioaccumulative potential No data available.

Mobility in soil No data available.

Other adverse effects No other adverse environmental effects (e.g. ozone depletion, photochemical ozone creation

potential, endocrine disruption, global warming potential) are expected from this component.

13. Disposal considerations

Disposal instructionsAvoid release to the environment. Do not allow this material to drain into sewers/water supplies.

Do not contaminate ponds, waterways or ditches with chemical or used container. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater. Dispose of contents/container

in accordance with local/regional/national/international regulations.

Material name: Temaril-P® Tablets

159 Version #: 03 Revision date: 05-04-2017 Issue date: 09-04-2013

Local disposal regulations Dispose in accordance with all applicable regulations.

Hazardous waste code None known.

Waste from residues / unused

products

Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions).

Disposai instructions

Contaminated packaging Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Annex II of MARPOL 73/78 and

Not applicable.

the IBC Code

15. Regulatory information

US federal regulations This product is a "Hazardous Chemical" as defined by the OSHA Hazard Communication

Standard, 29 CFR 1910.1200.

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1050)

Not regulated.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - Yes

Delayed Hazard - Yes Fire Hazard - No Pressure Hazard - No Reactivity Hazard - No

SARA 302 Extremely hazardous substance

Not listed.

SARA 311/312 Hazardous

No

chemical

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act

(SDWA)

Not regulated.

US state regulationsCalifornia Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material

is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)*AustraliaAustralian Inventory of Chemical Substances (AICS)YesCanadaDomestic Substances List (DSL)YesCanadaNon-Domestic Substances List (NDSL)NoChinaInventory of Existing Chemical Substances in China (IECSC)No

Material name: Temaril-P® Tablets
159 Version #: 03 Revision date: 05-04-2017 Issue date: 09-04-2013

Country(s) or region **Inventory name** On inventory (yes/no)* Europe European Inventory of Existing Commercial Chemical

Substances (EINECS)

Europe European List of Notified Chemical Substances (ELINCS) No Inventory of Existing and New Chemical Substances (ENCS) Japan No Korea Existing Chemicals List (ECL) No New Zealand New Zealand Inventory No

Philippines Philippine Inventory of Chemicals and Chemical Substances

(PICCS)

United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory No

No

16. Other information, including date of preparation or last revision

Issue date 09-04-2013 **Revision date** 05-04-2017

Version # 03

Disclaimer Zoetis Inc. believes that the information contained in this Safety Data Sheet is accurate, and while

> it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time. The information in the sheet was written based on the best knowledge and experience currently

available.

Revision information This document has undergone significant changes and should be reviewed in its entirety.

Material name: Temaril-P® Tablets SDS US

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).